Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sarcoma 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Histiocytic Sarcoma 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

enzalutamide 3cabazitaxel 3Prednisone 3Docetaxel 2Abiraterone Acetate 2rucaparib 1Zuclomiphene 1XRP6258 1Standard of Care 1LY3023414 1Injections 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Prostate Cancer Metastatic × LY3023414 × Clear all
NCT02407054 2021-05-11

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Eli Lilly and Company

Phase 2 Completed
142 enrolled 16 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡